PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

Puntos clave

• Synergistic cancer immunotherapy outcomes were observed with pd-l1-targeted photodynamic therapy and checkpoint blockade, enhancing treatment effectiveness.
• The combination led to significant immunogenic cell death, improving the overall response compared to monotherapies.
• Analysis across multiple tumor types demonstrated a notable increase in tumor regression rates with the combined intervention.
• This approach highlights the potential for improved cancer treatments, though further clinical validation is needed for widespread application.